Core Viewpoint - Ascentage Pharma-B (06855) saw a stock increase of over 3%, currently trading at HKD 64.35 with a transaction volume of HKD 46.048 million, following the announcement of positive clinical trial results for its novel drug Olarebactam (brand name: Nairike) in treating gastrointestinal stromal tumors (GIST) [1] Group 1: Clinical Trial Results - Ascentage Pharma announced the successful publication of research results for Olarebactam in the international journal "Signal Transduction and Targeted Therapy," which has an impact factor of 52.7 [1] - The study demonstrated that Olarebactam shows good efficacy and safety in treating SDH-deficient GIST, revealing a novel mechanism of action through lipid metabolism regulation [1] - The Phase I trial evaluated the safety and anti-tumor activity of Olarebactam in 66 patients with unresectable/metastatic GIST and other solid tumors, including 26 patients with SDH-deficient GIST who had failed prior treatment with tyrosine kinase inhibitors (TKIs) [1] - This trial is noted as the largest prospective clinical study to date targeting this rare subtype of GIST [1]
港股异动 | 亚盛医药-B(06855)涨超3% 首次揭示奥雷巴替尼通过调控脂质代谢发挥抗肿瘤作用全新机制